| 新福菌素联合卡铂、依托泊苷治疗老年非小细胞肺癌临床疗效观察 |
| |
| 引用本文： | 赵建清,邢立强,钱海红,李桂林.新福菌素联合卡铂、依托泊苷治疗老年非小细胞肺癌临床疗效观察[J].河北北方学院学报(医学版),2006,23(5):18-20. |
| |
| 作者姓名： | 赵建清 邢立强 钱海红 李桂林 |
| |
| 作者单位： | 1. 河北北方学院附属第一医院呼吸科,河北,张家口,075000
2. 河北北方学院实验中心,河北,张家口,075000 |
| |
| 摘 要： | 目的：评价国产新福菌素对老年非小细胞肺癌（NSCLC）的疗效和不良反应。方法：选取老年NSCLC病例81例，随机分治疗组43例给予新福菌素6μg／kg（第1～4d）。卡铂（CBP）300mg／m^2（第1d），依托泊苷（VP-16）100mg（第1～4或5d）静脉滴注；对照组38例单纯使用CBP和VP—16，剂量和方法同治疗组。21～28d为一个疗程．2～3个疗程评价疗效，随访缓解期和生存期。结果：治疗组有效率为53．49％，对照组有效率为31.58％，差异有显著性（P〈0．05）；中位缓解期分别为6和4．5个月，中位生存期分别为9和7个月．一年生存率分别为39．53％（17／43）和26．32％（10／38）。结论：新福菌素联合CBP、VP—16治疗老年NSCLC有较好的临床疗效及应用价值。
|
| 关 键 词： | 老年 非小细胞肺癌 化疗 新福菌素 卡铂 依托泊苷 |
| 文章编号： | 1673-1484（2006）05-0018-03 |
Clinical Study on Sinoactionomycin Combining Card Platinum and VP-16 in Treating Elderly Non- small Cell Lung Cancer |
| |
| ZHAO Jian-qing , XING Li-qiang , QIAN Hai-hong , et al.Clinical Study on Sinoactionomycin Combining Card Platinum and VP-16 in Treating Elderly Non- small Cell Lung Cancer[J].Journal of Hebei North University:Medical Edition,2006,23(5):18-20. |
| |
| Authors: | ZHAO Jian-qing XING Li-qiang QIAN Hai-hong |
| |
| Institution: | 1. Respiratory Department, The First Affiliated Hospital, Hebei North University, Zhangjiakou,075000,Hebei,China; 2. Hebei North University, Zhangjiakou, 075000,Hebei,China |
| |
| Abstract: | Objective:To investigate the curative effects and side-effect of domestic drug-Sinoactionomycin in treating elderly non-small cell lung cancer (NSCLC).Methods: 81 cases with elderly NSCLC were divided into two groups randomly,43 cases in the treatment group were administrated with Sinoactionomycin 6g/kg (1~4 day) combining card platinum (CBP) 300mg/m~ 2 (1st day), glucoside (VP-16) 100 mg (1~4 or 5 days) intravenously.38 cases in the control group were only treated with CBP and vp-16 and the dosage were same with that of treatment group.21~28 days were taken as a treatment cycle and the curative effects were studied after 2~3 cycles.The relievable and survival periods were investigated as well.Results: The effectiveness for treatment troup is 53.49%, effectiveness for control group is 31.58%, the difference has the significance (P<0.05); The central relievable period is 6 and 4.5 months respectively, and the central survival period is 9 and 7 months respectively,on year survival rate respectively is 39.53% (17,/43) and 26.32% (10,/38). Conclusion: Sinoactionomycin combining CBP,and VP-16 has good clinical curative effect in treating elderly NSCLC and has the good clinical practice value. |
| |
| Keywords: | Elderly Non-small cell lung cancer Chemotherapy Sinoactlonomycin Card platinum VP-16 |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
